论文部分内容阅读
[目的]观察肝动脉化疗栓塞术(TACE)联合卡培他滨治疗老年结直肠癌术后肝转移患者的疗效及不良反应。[方法]入选66例老年结直肠癌肝转移患者,依据治疗方案分为卡培他滨组(对照组,34例)及TACE+卡培他滨组(联合治疗组,32例),以RECIST标准评价近期疗效,以CTCAE 4.0版评价毒性反应,以卡氏评分评价患者生活质量,随访记录患者生存时间。[结果]联合治疗组、对照组近期有效率分别为75.00%、61.76%,2组比较差异有统计学意义(P<0.05)。联合治疗组的3年中位生存时间为21个月,优于对照组的16个月。2组患者经过治疗后生活质量方面都得到有效提高,2组治疗后生活质量比较差异无统计学意义。2组均未出现Ⅲ度及以上不良反应。[结论]在老年结直肠癌术后肝转移的治疗中,TACE联合卡培他滨治疗是一种安全、有效的治疗模式。
[Objective] To observe the efficacy and adverse reactions of transcatheter arterial chemoembolization (TACE) and capecitabine in the treatment of postoperative liver metastasis of elderly patients with colorectal cancer. [Methods] Sixty-six elderly patients with liver metastasis of colorectal cancer were divided into capecitabine group (control group, 34 cases) and TACE + capecitabine group (combination group, 32 cases) according to RECIST standard Evaluation of the recent curative effect, to evaluate the toxicity of CTCAE version 4.0, to evaluate the quality of life of patients with Karnofstal score, follow-up record of patient survival time. [Results] The effective rates of the combination therapy group and the control group were 75.00% and 61.76% respectively, there was significant difference between the two groups (P <0.05). The 3-year median survival time for the combination therapy group was 21 months, which was better than the control group for 16 months. The quality of life of the two groups of patients was effectively improved after treatment. There was no significant difference in quality of life between the two groups after treatment. No adverse reactions occurred in grade 3 and above in both groups. [Conclusion] TACE plus capecitabine is a safe and effective treatment for the treatment of postoperative liver metastases in elderly patients with colorectal cancer.